Literature DB >> 30051565

Prevalence of diagnosed HIV infection among persons with hepatitis C virus infection: England, 2008-2014.

G Ireland1,2, V Delpech1,2, P Kirwan1, S Croxford1, S Lattimore1,2, C Sabin2,3, K Porter2,3, S Mandal1,2, R Simmons1,2.   

Abstract

OBJECTIVES: In persons with hepatitis C virus (HCV) infection, HIV coinfection leads to faster progression to advanced liver disease. The aim of our study was to estimate diagnosed HIV prevalence among people with evidence of current HCV infection (polymerase chain reaction positive) and examine predictors of coinfection.
METHODS: Adults (≥ 15 years old) with a current HCV infection reported to the Public Health England (PHE) sentinel surveillance of blood-borne viruses were linked to the PHE national HIV database using a deterministic methodology. Descriptive and multivariate analyses were conducted.
RESULTS: Between 2008 and 2014, 5.0% (999/20 088) of adults with a current HCV infection were diagnosed with HIV coinfection. The majority acquired HIV through sex between men (441; 64.9%), followed by injecting drug use (153; 22.5%) and heterosexual contact (84; 12.4%). Of persons who were coinfected, 65.5% had been diagnosed with HIV infection > 6 months before their HCV diagnosis, 41.4% of whom had a negative anti-HCV test between their HIV and HCV diagnoses. In a multivariable model among persons with current HCV infection, an HIV diagnosis was more likely among men [adjusted odds ratio (aOR) 3.29; 95% confidence interval (CI) 2.60-4.16] and persons of black ethnicity (aOR 3.19; 95% CI 1.36-7.46), and less likely among older adults (aOR 0.85 per 10-year increase; 95% CI 0.79-0.92) and persons of Asian ethnicity (aOR 0.59; 95% CI 0.41-0.86).
CONCLUSIONS: Our results indicate that the majority of diagnosed HIV and current HCV coinfections are among men who have sex with men. Safer sex campaigns should include awareness of transmission of HCV among MSM living with HIV.
© 2018 British HIV Association.

Entities:  

Keywords:  HIV; coinfection; hepatitis C; injecting drug use; men who have sex with men

Mesh:

Year:  2018        PMID: 30051565     DOI: 10.1111/hiv.12662

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  5 in total

1.  The Prevalence of Human Immunodeficiency Virus Coinfection Among Patients Newly Diagnosed With Chronic Hepatitis B or C in Denmark: A Nationwide Cohort Study.

Authors:  Sofie Hallager; Andreas Lundh; Steen Ladelund; Jan Gerstoft; Alex Lund Laursen; Mette Rye Clausen; Ulla Balslev; Nina Weis
Journal:  Open Forum Infect Dis       Date:  2018-11-21       Impact factor: 3.835

2.  Impact of HIV and chronic kidney disease comorbidities on hepatitis C treatment choices, drug-drug interactions and hepatitis C cure.

Authors:  Salamat Ali; Tofeeq Ur-Rehman; Eleri Lougher; David Mutimer; Mashhood Ali; Vibhu Paudyal
Journal:  Int J Clin Pharm       Date:  2020-02-25

3.  Hepatitis C Co-infection in People Living With HIV-Epidemiologic Differences Between Men Who Have Sex With Men MSM and Non-MSM.

Authors:  Tsz Ho Kwan; Bonnie Chun Kwan Wong; Ka Hing Wong; Shui Shan Lee
Journal:  Front Public Health       Date:  2022-06-03

Review 4.  The global and regional prevalence of hepatitis C and B co-infections among prisoners living with HIV: a systematic review and meta-analysis.

Authors:  Hasan Ahmadi Gharaei; Mohammad Fararouei; Ali Mirzazadeh; Golnaz Sharifnia; Marzieh Rohani-Rasaf; Dariush Bastam; Jamileh Rahimi; Mostafa Kouhestani; Shahab Rezaian; Mostafa Dianatinasab
Journal:  Infect Dis Poverty       Date:  2021-07-01       Impact factor: 4.520

5.  Detection and Characterization of Human Pegivirus 2, Vietnam.

Authors:  Nguyen To Anh; Nguyen Thi Thu Hong; Le Nguyen Truc Nhu; Tran Tan Thanh; Catherine Anscombe; Le Ngoc Chau; Tran Thi Thanh Thanh; Chuen-Yen Lau; Direk Limmathurotsakul; Nguyen Van Vinh Chau; H Rogier van Doorn; Xutao Deng; Motiur Rahman; Eric Delwart; Thuy Le; Guy Thwaites; Le Van Tan
Journal:  Emerg Infect Dis       Date:  2018-11       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.